SCHEMBL19660422

SCHEMBL19660422

O=C(O)c1cn2cccc(I)c2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.54
PTGS2 P35354 1/20 0.54
DHODH Q02127 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
KDM4E B2RXH2 3/20 0.38
TSHR P16473 2/20 0.38
ALOX15 P16050 1/20 0.38
ACMSD Q8TDX5 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
CREBBP Q92793 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
ALDH1A2 O94788 2/20 0.35
ALDH1A3 P47895 2/20 0.35
ALDH1A1 P00352 2/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3305733 0.81 PTGS1 (0.56) PTGS1PTGS2DHODHRXFP1KDM4E
SCHEMBL8373781 0.80 PTGS1 (0.54) PTGS1PTGS2DHODHRXFP1KDM4E
SCHEMBL31211453 0.80 PTGS1 (0.54) PTGS1PTGS2DHODHRXFP1KDM4E
SCHEMBL1758978 0.80 RXFP1 (0.56) PTGS1PTGS2RXFP1KDM4ETSHR
SCHEMBL30556624 0.80 PTGS1 (0.54) PTGS1PTGS2DHODHRXFP1KDM4E
SCHEMBL26922447 0.78 PTGS1 (0.44) PTGS1PTGS2DHODHRXFP1KDM4E
SCHEMBL2505187 0.78 PTGS1 (0.51) PTGS1PTGS2DHODHRXFP1KDM4E
SCHEMBL10022660 0.78 PTGS1 (0.51) PTGS1PTGS2DHODHRXFP1KDM4E
SCHEMBL1583802 0.77 PTGS1 (0.41) PTGS1PTGS2DHODHRXFP1KDM4E
SCHEMBL2832275 0.76 PTGS1 (0.50) PTGS1PTGS2DHODHRXFP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017205538-A1 PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER GENENTECH, INC. (US) 2017-11-30 WO disclosed